May 13, 2025 Discovery Toxicology
May 14, 2025 morning Discovery Toxicology
May 14, 2025 afternoon Development Toxicology
May 15, 2025 Development Toxicology
 

DISCOVERY TOXICOLOGY WORKSHOP - TUESDAY MAY 13, 2025

Session Topic Speaker Company Time
Registration and Lunch     12:00-1:00
Conference Opening and Plenary Speaker Introduction

 

  1:00-1:10
Plenary Lecture: Integrating Generative AI with Active Learning to Power Next Generation Drug Discovery Richard Bonneau Genentech 1:10-1:55

Session I:  Digital Pathology & Spatial Transcriptomics (Applications)

Moderators:  Yoav Timsit, Novartis, Darcy Clark, Merck & Jodi Goodwin, Takeda

Session Topic Speaker Company Time
Session Introduction     1:55-2:00
Comparison of Supervised and Unsupervised Machine Learning Scoring of Histology Images Tom Forest Merck 2:00-2:30
Model Detection of the Seen and Unseen: A Multi-paradigm Approach to Histologic Anomaly Detection Fangyao Hu Genentech 2:30-3:00
Vendor Talk: TBA TBA TBA 3:00-3:25
Break       3:25-3:50
Title TBA Byunghak (BK) Kang Novartis 11:15-11:45
Vendor Talk: TBA

TBA

TBA 4:20-4:30
Context-specific Applications Across Spatial Transcriptomic Platform David Gallegos Takeda 4:30-5:00
Day 1 Closing Remarks     5:00-5:10
DISCOVERY TOXICOLOGY WORKSHOP - WEDNESDAY MAY 14, 2025
Registration and Breakfast  7:00-8:00

Session II: New Modalities & Traditional Molecules - Case Studies

Moderators:  Connie Wu, Genentech, Jonathan Heyen, Treeline Bio & Helen Yu, Vertex

Session Introduction      8:00 - 8:05
Safety Considerations for Developing Molecular Glues and other Targeted Protein Degraders Jessica Sims Genentech 8:05 - 8:35
Global Off-Target Profiling of Targeted Protein Degraders with a Cell-Based Proteomics Platform Xiaoting Wang Amgen 8:35 - 9:05
Talk title TBA TBA TBA 9:05 - 9:35
Break       9:35 - 9:55

Session III: 4th Generation of ADC's

Moderators: Rama Pai, Merck & Prathap Kumar Mahalingaiah, AstraZeneca

Session Topic Speaker Company Time
Session Introduction     9:55 - 10:00
Integrating PKPD Modeling and Clinical Toxicity Meta-Analysis towards Therapeutic Index prediction for Antibody-Drug Conjugate Mahua Roy AstraZeneca 10:00 - 10:25
Nonclinical Safety Assessment of Antibody-Oligo Conjugates from IND-enabling through Late-Stage Clinical Trials Laura Leung Avidity Biosciences 10:25 - 10:50
The Use of In Vitro Assays for Novel Payload Selection in New-Generation ADCs Diana Lac Genentech 10:50 - 11:15
Talk Title TBA Haley Neff-LaFord Pfizer 11:15 - 11:40
Vendor Talk: TBA TBA TBA 11:40-12:05
Lunch   12:05-1:25
DEVELOPMENT TOXICOLOGY WORKSHOP- WEDNESDAY MAY 15, 2024
Workshop Introduction and Speaker Introduction     1:25 - 1:35
Plenary Lecture: Harnessing Generative AI in Nonclinical Safety Evaluation Zhichao Liu Boehringer Ingelheim 1:35 - 2:15

Session IV: Revolutionizing Toxicology: Virtual Controls, Digital Pathology, NAMs, and Species Alternatives in Drug Development

Moderators: Betty Pettersen, Alexion, Yuan Lu, CinRx Pharma & Surekha Akella, AbbVie

Session Introduction      2:15 - 2:20
Opportunities and Insights From Pharma On the Use of NAMs to Replace Large Animal Studies in Nonclinical Safety Assessments for Biotherapeutics Kim Homan Genentech 2:20 - 2:40
Break   2:40 - 3:00
Vendor Talk: TBA TBA TBA 3:00 - 3:10
Insights into Building a Robust Virtual Control Database and Selection Methods for Use on Retrospective Analysis of Nonclinical Safety Assessment Studies Jillian Wendel LabCorp 3:10 - 3:30
Title TBA TBA TBA 3:30 - 3:50
Title TBA TBA TBA 3:50 - 4:10
Panel Discussion - Session IV Speakers     4:10 - 4:30
Poster Session and Reception     4:30 - 5:45
DEVELOPMENT TOXICOLOGY WORKSHOP-THURSDAY MAY 15, 2025
Breakfast  7:00 - 8:00
Workshop Introduction     8:00 - 8:05

Session V: New Generations ADC's ( Antibody-siRNA-Conjugates (ARC), Peptide-drug Conjugates (PDC)

Moderators: Christine Mollica, Amgen, Ed Dere, Genentech, Daniella Pizarro, Merck & Pia Kasperkovitz, Bright Peak Therapeutics

Session Introduction       8:05 - 8:10
Nonclinical Safety Strategies for ADC Development - Looking back to move forward Christina de Zafra Merck 8:10 - 8:40
Unique Platform Toxicities of ADCs - Learnings Over the Last Decade Magali Guffroy AbbVie 8:40 - 9:10
Case Study: Regulatory Interactions and Path to IND for a Novel Antibody-Protein Conjugate Pia Kasperkovitz Bright Peak Therapeutics 9:10 - 9:40
AM Break     9:40 - 10:00
Vendor Talk: TBA TBA TBA 10:00 - 10:25

Session VI: Pioneering Cell and Gene Therapies: Expanding Horizons Beyond CAR-T

Moderators: Heather Kowalski, BlueRock Therapeutics, Joe Cichocki, Vertex & Michael Santostefano, Merck

Session Topic Speaker Company Time
 Session Introduction      10:25 - 10:30
Protecting Allogeneic Transplants from Immune Rejection is the Key to Bringing Cell-Based Therapies to Patients Sonja Schrepfer Sana Biotechnology 10:30 - 11:00
Supporting Clinical Trials for Non-Cancer Cell Therapies - From Patient and Treatment Plans, Backwards Lauren Black CRL 11:00 - 11:30
Title TBA TBA TBA 11:30 - 12:00
Conference Closing     12:00 - 12:05

Workshops

Discovery

Development

Registration

Click here to register for the APT 2025 conference.

May 13-14, 2025 Discovery Toxicology

May 14-15, 2025 Development Toxicology

Genentech, South San Francisco, CA

 

The Boston Society

The Boston Society (R) is an internationally-recognized NON-PROFIT organization dedicated to bringing the best scientific ideas to industrial practice through focused, timely workshops and conferences. 501(c)3

Updates

Sign Up Today!

Privacy Policy